SynthesisBlood2015
Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.
Synthesis in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Systematic Literature Review of Economic Evaluations of Treatment Alternatives in Chronic Lymphocytic Leukemia.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Pooled it
- Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Pooled it
- How relevant are social costs in economic evaluations? The case of Alzheimer's disease.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- Caregivers' proxy assessments of health-related quality of life in patients with hematologic malignancies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature.Journal of the National Cancer Institute. Monographs · 2022Review
- Considering the societal perspective in economic evaluations: a systematic review in the case of depression.Health economics review · 2020Review
- Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?Current hematologic malignancy reports · 2019Review
- Balancing patient value and payer cost in hematologic malignancies: can it be done?Expert review of pharmacoeconomics & outcomes research · 2018Article
- Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients.BMC infectious diseases · 2017Article
- The high price of anticancer drugs: origins, implications, barriers, solutions.Nature reviews. Clinical oncology · 2017Review
- Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.Journal of the National Cancer Institute · 2017Review
- Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2016Article
- Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.The oncologist · 2016Article
- Engineered T cells: the promise and challenges of cancer immunotherapy.Nature reviews. Cancer · 2016Review
- Future paradigms for precision oncology.Oncotarget · 2016Review
- CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice.Molecular therapy oncolytics · 2016Article
- How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses.Blood · 2015Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
We analyzed cost-effectiveness studies related to hematologic malignancies from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), focusing on studies of innovative therapies. Studies that met inclusion criteria were categorized by 4 cancer types (chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma) and 9 treatment agents (interferon-α, alemtuzumab, bendamustine, bortezomib, dasatinib, imatinib, lenalidomide, rituximab alone or in combination, and thalidomide). We examined study characteristics and stratified cost-effectiveness ratios by type of cancer, treatment, funder, and year of study publication. Twenty-nine studies published in the years 1996-2012 (including 44 cost-effectiveness ratios) met inclusion criteria, 22 (76%) of which were industry funded. Most ratios fell below $50,000 per quality-adjusted life-years (QALY) (73%) and $100,000/QALY (86%). Industry-funded studies (n = 22) reported a lower median ratio ($26,000/QALY) than others (n = 7; $33,000/QALY), although the difference was not statistically significant. Published data suggest that innovative treatments for hematologic malignancies may provide reasonable value for money.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.